CORMEDIX INC. Cash and Cash Equivalents, Period Increase (Decrease)
CORMEDIX INC. (CRMD) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$4.15 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-05-11
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$4.15M, a 755.22% decline year-over-year.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was -$3.79M, a 133.90% decline year-over-year.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $5.58M, a 220.45% increase year-over-year.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$3.70M.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$1.27M, a 117.53% decline from fiscal 2018.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $7.24M, a 212.89% increase from fiscal 2017.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $2.32M.
- CORMEDIX INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.75M, a 150.19% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 59 month | Cash and Cash Equivalents, Period Increase (Decrease) 62 month | Cash and Cash Equivalents, Period Increase (Decrease) 65 month | Cash and Cash Equivalents, Period Increase (Decrease) 68 month | Cash and Cash Equivalents, Period Increase (Decrease) 71 month | Cash and Cash Equivalents, Period Increase (Decrease) 74 month | Cash and Cash Equivalents, Period Increase (Decrease) 77 month | Cash and Cash Equivalents, Period Increase (Decrease) 80 month | Cash and Cash Equivalents, Period Increase (Decrease) 83 month | Cash and Cash Equivalents, Period Increase (Decrease) 89 month | Cash and Cash Equivalents, Period Increase (Decrease) 92 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -$4.15M 10-Q · filed 2020-05-11 | -$7.94M derived: sum of 2 quarters · filed 2020-05-11 | -$2.36M derived: sum of 3 quarters · filed 2020-05-11 | -$6.05M derived: sum of 4 quarters · filed 2020-05-11 | |||||||||||
| 2019-12-31 | -$3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.79M derived: sum of 2 quarters · filed 2020-03-16 | -$1.90M derived: sum of 3 quarters · filed 2020-03-16 | -$1.27M 10-K · filed 2020-03-16 | |||||||||||
| 2019-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.89M derived: sum of 2 quarters · filed 2019-11-14 | $2.52M 10-Q · filed 2019-11-14 | $13.70M derived: sum of 4 quarters · filed 2020-05-11 | |||||||||||
| 2019-06-30 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$3.06M 10-Q · filed 2019-08-14 | $8.12M derived: sum of 3 quarters · filed 2020-05-11 | $9.86M derived: sum of 4 quarters · filed 2020-05-11 | |||||||||||
| 2019-03-31 | $633.23K 10-Q · filed 2020-05-11 | $11.81M derived: sum of 2 quarters · filed 2020-05-11 | $13.56M derived: sum of 3 quarters · filed 2020-05-11 | $10.09M derived: sum of 4 quarters · filed 2020-05-11 | |||||||||||
| 2018-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $12.92M derived: sum of 2 quarters · filed 2020-03-16 | $9.46M derived: sum of 3 quarters · filed 2020-03-16 | $7.24M 10-K · filed 2020-03-16 | |||||||||||
| 2018-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$1.72M derived: sum of 2 quarters · filed 2019-11-14 | -$3.94M 10-Q · filed 2019-11-14 | $1.23M derived: sum of 4 quarters · filed 2019-11-14 | |||||||||||
| 2018-06-30 | -$3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$5.68M 10-Q · filed 2019-08-14 | -$510.60K derived: sum of 3 quarters · filed 2019-08-14 | -$3.24M derived: sum of 4 quarters · filed 2019-08-14 | |||||||||||
| 2018-03-31 | -$2.22M 10-Q · filed 2019-05-13 | $2.95M derived: sum of 2 quarters · filed 2019-05-29 | $224.65K derived: sum of 3 quarters · filed 2019-05-29 | $1.34M derived: sum of 4 quarters · filed 2019-05-29 | |||||||||||
| 2017-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-05-29 | $2.44M derived: sum of 2 quarters · filed 2019-05-29 | $3.56M derived: sum of 3 quarters · filed 2019-05-29 | $2.32M 10-K · filed 2019-05-29 | |||||||||||
| 2017-09-30 | -$2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$1.61M derived: sum of 2 quarters · filed 2018-11-14 | -$2.85M 10-Q · filed 2018-11-14 | -$4.61M derived: sum of 4 quarters · filed 2018-11-14 | |||||||||||
| 2017-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$127.10K 10-Q · filed 2018-08-14 | -$1.89M derived: sum of 3 quarters · filed 2018-08-14 | -$4.08M derived: sum of 4 quarters · filed 2018-08-14 | |||||||||||
| 2017-03-31 | -$1.25M 10-Q · filed 2018-05-15 | -$3.01M derived: sum of 2 quarters · filed 2018-05-15 | -$5.20M derived: sum of 3 quarters · filed 2018-05-15 | -$6.37M derived: sum of 4 quarters · filed 2018-05-15 | |||||||||||
| 2016-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$3.96M derived: sum of 2 quarters · filed 2018-03-19 | -$5.12M derived: sum of 3 quarters · filed 2018-03-19 | -$3.75M 10-K · filed 2018-03-19 | |||||||||||
| 2016-09-30 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$3.36M derived: sum of 2 quarters · filed 2017-11-09 | -$1.99M 10-Q · filed 2017-11-09 | -$4.42M derived: sum of 4 quarters · filed 2017-11-09 | |||||||||||
| 2016-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $203.56K 10-Q · filed 2017-08-09 | -$2.23M derived: sum of 3 quarters · filed 2017-08-09 | -$12.09M derived: sum of 4 quarters · filed 2017-08-09 | |||||||||||
| 2016-03-31 | $1.37M 10-Q · filed 2017-05-10 | -$1.06M derived: sum of 2 quarters · filed 2017-05-10 | -$10.93M derived: sum of 3 quarters · filed 2017-05-10 | $4.39M derived: sum of 4 quarters · filed 2017-05-10 | |||||||||||
| 2015-12-31 | -$2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$12.29M derived: sum of 2 quarters · filed 2017-03-16 | $3.02M derived: sum of 3 quarters · filed 2017-03-16 | $7.48M 10-K · filed 2017-03-16 | |||||||||||
| 2015-09-30 | -$9.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.45M derived: sum of 2 quarters · filed 2016-11-09 | $9.91M 10-Q · filed 2016-11-09 | $8.33M derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||
| 2015-06-30 | $15.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $19.77M 10-Q · filed 2016-08-04 | $18.19M derived: sum of 3 quarters · filed 2017-03-16 | $16.46M derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||
| 2015-03-31 | $4.46M 10-Q · filed 2016-05-10 | $2.88M derived: sum of 2 quarters · filed 2017-03-16 | $1.15M derived: sum of 3 quarters · filed 2017-03-16 | -$390.07K derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||
| 2014-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$3.31M derived: sum of 2 quarters · filed 2017-03-16 | -$4.85M derived: sum of 3 quarters · filed 2017-03-16 | $1.97M 10-K · filed 2017-03-16 | |||||||||||
| 2014-09-30 | -$1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$3.27M derived: sum of 2 quarters · filed 2015-11-12 | $3.55M 10-Q · filed 2015-11-12 | $5.44M derived: sum of 4 quarters · filed 2015-11-12 | |||||||||||
| 2014-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $5.28M 10-Q · filed 2015-08-06 | $7.17M derived: sum of 3 quarters · filed 2015-08-06 | $7.49M derived: sum of 4 quarters · filed 2015-08-06 | |||||||||||
| 2014-03-31 | $6.82M 10-Q · filed 2015-05-07 | $8.71M derived: sum of 2 quarters · filed 2015-05-07 | $9.03M derived: sum of 3 quarters · filed 2015-05-07 | $8.50M derived: sum of 4 quarters · filed 2015-05-07 | $9.19M 10-Q · filed 2014-05-15 | ||||||||||
| 2013-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $2.22M derived: sum of 2 quarters · filed 2015-03-12 | $1.68M derived: sum of 3 quarters · filed 2015-03-12 | $1.54M 10-K · filed 2015-03-12 | $2.37M 10-K · filed 2014-03-31 | ||||||||||
| 2013-09-30 | $324.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$209.67K derived: sum of 2 quarters · filed 2014-11-13 | -$352.42K 10-Q · filed 2014-11-13 | -$509.29K derived: sum of 4 quarters · filed 2014-11-13 | $483.05K 10-Q/A · filed 2014-03-04 | ||||||||||
| 2013-06-30 | -$534.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$677.07K 10-Q · filed 2014-08-14 | -$833.94K derived: sum of 3 quarters · filed 2014-08-14 | -$735.53K derived: sum of 4 quarters · filed 2014-08-14 | $158.41K 10-Q/A · filed 2014-03-04 | ||||||||||
| 2013-03-31 | -$142.75K 10-Q · filed 2014-05-15 | -$299.62K derived: sum of 2 quarters · filed 2014-05-15 | -$201.22K derived: sum of 3 quarters · filed 2014-05-15 | -$1.16M derived: sum of 4 quarters · filed 2014-05-15 | $692.72K 10-Q/A · filed 2014-03-04 | ||||||||||
| 2012-12-31 | -$156.87K derived: 10-K 12 month − 10-Q/A 9 month · filed 2014-03-31 | -$58.47K derived: sum of 2 quarters · filed 2014-03-31 | -$1.02M derived: sum of 3 quarters · filed 2014-03-31 | -$1.15M 10-K · filed 2014-03-31 | $835.47K 10-K/A · filed 2014-03-04 | ||||||||||
| 2012-09-30 | $98.41K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2014-03-04 | -$862.85K derived: sum of 2 quarters · filed 2014-03-04 | -$992.99K 10-Q/A · filed 2014-03-04 | -$1.90M derived: sum of 4 quarters · filed 2014-03-04 | $992.34K 10-Q/A · filed 2013-03-27 | ||||||||||
| 2012-06-30 | -$961.26K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2014-03-04 | -$1.09M 10-Q/A · filed 2014-03-04 | -$2.00M derived: sum of 3 quarters · filed 2014-03-04 | -$3.84M derived: sum of 4 quarters · filed 2014-03-04 | $893.94K 10-Q/A · filed 2012-09-06 | ||||||||||
| 2012-03-31 | -$130.14K 10-Q/A · filed 2014-03-04 | -$1.03M derived: sum of 2 quarters · filed 2014-03-04 | -$2.88M derived: sum of 3 quarters · filed 2014-03-04 | -$4.71M derived: sum of 4 quarters · filed 2014-03-04 | $1.86M 10-Q · filed 2012-05-15 | ||||||||||
| 2011-12-31 | -$904.59K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-03-04 | -$2.75M derived: sum of 2 quarters · filed 2014-03-04 | -$4.58M derived: sum of 3 quarters · filed 2014-03-04 | -$6.30M 10-K/A · filed 2014-03-04 | $1.99M 10-K/A · filed 2012-04-26 | ||||||||||
| 2011-09-30 | -$1.85M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2013-03-27 | -$3.67M derived: sum of 2 quarters · filed 2013-03-27 | -$5.39M 10-Q/A · filed 2013-03-27 | -$6.63M derived: sum of 4 quarters · filed 2013-03-27 | $2.89M 10-Q · filed 2011-11-10 | ||||||||||
| 2011-06-30 | -$1.83M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-06 | -$3.55M 10-Q/A · filed 2012-09-06 | -$4.78M derived: sum of 3 quarters · filed 2012-09-06 | -$5.85M derived: sum of 4 quarters · filed 2012-09-06 | $4.74M 10-Q · filed 2011-08-09 | ||||||||||
| 2011-03-31 | -$1.72M 10-Q · filed 2012-05-15 | -$2.96M derived: sum of 2 quarters · filed 2012-05-15 | -$4.02M derived: sum of 3 quarters · filed 2012-05-15 | ||||||||||||
| 2010-12-31 | -$1.24M derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-04-26 | -$2.30M derived: sum of 2 quarters · filed 2012-04-26 | $6.78M 10-K/A · filed 2012-04-26 | ||||||||||||
| 2010-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $8.02M 10-Q · filed 2011-11-10 | |||||||||||||
| 2010-06-30 | $9.08M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |